Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Elfun Trusts Significantly Reduces Stake in Broadcom Inc by 60.7%
12:00pm, Monday, 24'th Nov 2025
Exploring Elfun Trusts (Trades, Portfolio)' Strategic Moves in Q3 2025 Elfun Trusts (Trades, Portfolio) recently submitted its N-PORT filing for the third quar
Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3
04:00pm, Wednesday, 19'th Nov 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Fi
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
10:02am, Tuesday, 18'th Nov 2025
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Columbia Contrarian Core Fund Q3 2025 Performance Review
06:40am, Tuesday, 18'th Nov 2025
The fund underperformed its benchmark, the Russell 1000 Index, during the third quarter. Videogame producer Electronic Art's was the top contributor during the period. Elevance Health was the top unde
Vertex Pharmaceuticals Incorporated $VRTX Stake Reduced by Bridger Management LLC
03:51am, Tuesday, 18'th Nov 2025
Bridger Management LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 54.3% during the undefined quarter, according to the company in its most recent 13F filing with th
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
04:05pm, Monday, 17'th Nov 2025
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
02:31pm, Sunday, 16'th Nov 2025
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with
My 3 Favorite Stocks to Buy Right Now
09:30am, Sunday, 16'th Nov 2025
Amazon has formidable moats and multiple avenues for growth. Enbridge offers stability, a generous dividend, and growth opportunities related to AI.
Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update
05:09am, Wednesday, 12'th Nov 2025
Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript
02:41pm, Tuesday, 11'th Nov 2025
Vertex Pharmaceuticals Incorporated ( VRTX ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Pa
Vertex Pharmaceuticals Incorporated ( VRTX ) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio November 8, 2025 8:00 PM EST Company Participants Susie Lisa -
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
10:00am, Friday, 07'th Nov 2025
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Artisan Global Opportunities Fund Q3 2025 Portfolio Update
08:10am, Thursday, 06'th Nov 2025
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campa
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
12:36pm, Wednesday, 05'th Nov 2025
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge.
